4.6 Review

Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis

Journal

FRONTIERS IN NEUROLOGY
Volume 9, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fneur.2018.00888

Keywords

neuromyelitis optica; aquaporin-4 antibodies; MOG-encephalomyelitis; diagnostic criteria; immunosuppressive treatment

Funding

  1. Bayer
  2. Novartis
  3. Biogen Idec
  4. Teva
  5. Sanofi-Aventis/Genzyme
  6. Merck Serono
  7. Alexion
  8. Chugai
  9. MedImmune
  10. Shire
  11. German Research Council
  12. Werth Stiftung of the City of Cologne
  13. German Ministry of Education and Research
  14. Arthur Arnstein Stiftung Berlin
  15. EU FP7 Framework Program
  16. Arthur Arnstein Foundation Berlin
  17. Guthy Jackson Charitable Foundation
  18. National Multiple Sclerosis of the USA

Ask authors/readers for more resources

Neuromyelitis optica spectrum disorders (NMOSD) are autoantibody mediated chronic inflammatory diseases. Serum antibodies (Abs) against the aquaporin-4 water channel lead to recurrent attacks of optic neuritis, myelitis and/or brainstem syndromes. In some patients with symptoms of NMOSD, no AQP4-Abs but Abs against myelin-oligodendrocyte-glycoprotein (MOG) are detectable. These clinical syndromes are now frequently referred to as MOG-encephalomyelitis (MOG-EM). Here we give an overview on current recommendations concerning diagnosis of NMOSD and MOG-EM. These include antibody and further laboratory testing, MR imaging and optical coherence tomography. We discuss therapeutic options of acute attacks as well as longterm immunosuppressive treatment, including azathioprine, rituximab, and immunoglobulins.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available